Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD

Hao Zhao, Miao-yan Zhang, Kai-ni Shen, Jun Feng, Xin-xin Cao, Ming-hui Duan, Dao-bin Zhou, Lu Zhang, Jian Li

Blood (2023) 141 (21): 2654–2657.

https://doi.org/10.1182/blood.2023020009

Published: 2023

Includes: Supplemental data

Journal Articles

The Design of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea (HU)

Jie Jin, Lei Zhang, Su-Jiang Zhang, Suning Chen, Ming-hui Duan, Jingjing Zhang, Wei Wang, Warren Shen, Oleh Zagrijtschuk, Raymond Urbanski, Albert Qin, Zhijian Xiao

Blood (2021) 138 (Supplement 1): 4628.

https://doi.org/10.1182/blood-2021-146449

Published: 2021

Journal Articles

A Prospective, Multicenter Study of Bortezomib, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Idiopathic Multicentric Castleman's Disease

Lu Zhang, MD, Ming-nan Jia, MD, Ai-lin Zhao, MD, Jun Feng, MD, Xin-xin Cao, MD, Yan Zhang, MD, Ming-hui Duan, MD, Dao-Bin Zhou, Yujun Dong, MD, Jian Li, MD

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-140115

Published: 2020

Journal Articles

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Paola Guglielmelli, MD, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Ming-hui Duan, MD, Haitao Meng, MD PhD, Ling Pan, MD PhD, Guangsheng He, MD PhD, Srdan Verstovsek, MD PhD, Françoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Dietger Niederwieser, MD PhD, Anna Marina Liberati, MD, Claire Harrison, DM, FRCP, FRCPath, Pantelia Roussou, MSc, Monika Wroclawska, MD, Kevin Majidi, Peter AW te Boekhorst, MD PhD, Heinz Gisslinger, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137742

Published: 2020

Journal Articles

Treatment Outcome and Prognostic Factors for Adult Langerhans Cell Histiocytosis

Xinxin Cao, MD, Ming-hui Duan, MD, Ai-lin Zhao, Hao Cai, Jia Chen, Xue-min Gao, Ting Liu, Hua-cong Cai, MD, Lu Zhang, Jian Sun, MD, Zhi-yong Liang, MD, Dao-Bin Zhou, Jian Li, MD

Blood (2020) 136 (Supplement 1): 38.

https://doi.org/10.1182/blood-2020-138426

Published: 2020

Journal Articles

Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China

Congli Zhang, Xin-xin Cao, Dong-zhu Li, Jun Feng, MD, Lu Zhang, MD, Yan Zhang, Ming-hui Duan, MD, Miao Chen, MD, Chen Yang, Wei Wang, Dao-Bin Zhou, Jian Li, MD

Blood (2019) 134 (Supplement_1): 2127.

https://doi.org/10.1182/blood-2019-125505

Published: 2019

Journal Articles

Methotrexate and Cytarabine for Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study

Xinxin Cao, Jian Li, MD, Ai-lin Zhao, Xue-min Gao, Hua-cong Cai, MD, Lu Zhang, MD, Yan Zhang, MD, Jun Feng, MD, Miao Chen, MD, Tie-nan Zhu, MD, Na Niu, Jian Sun, MD, Zhi-yong Liang, MD, Dao-Bin Zhou, Ming-hui Duan, MD

Blood (2019) 134 (Supplement_1): 294.

https://doi.org/10.1182/blood-2019-122220

Published: 2019

Journal Articles

Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease

Lu Zhang, Ai-lin Zhao, Ming-hui Duan, Zhi-yuan Li, Xin-xin Cao, Jun Feng, Dao-bin Zhou, Ding-rong Zhong, David C. Fajgenbaum, Jian Li

Blood (2019) 133 (16): 1720–1728.

https://doi.org/10.1182/blood-2018-11-884577

Published: 2019

Journal Articles

Clinical and PET Responses to Long-Term High-Dose Interferon-α Treatment Among Patients with Erdheim-Chester Disease

Xinxin Cao, Na Niu, Jian Sun, Hao Cai, Feng-dan Wang, Yi-ning Wang, Ding-rong Zhong, Ming-hui Duan, MD, Dao-bin Zhou, MD, Jian Li, MD

Blood (2018) 132 (Supplement 1): 5215.

https://doi.org/10.1182/blood-2018-99-114040

Published: 2018

Journal Articles

Peritransplant Complications and Long-Term Outcomes of Patients with Newly Diagnosed POEMS Syndrome after Upfront Autologous Stem Cell Transplantation

Jian Li, MD, Ming-hui Duan, MD, Wei Zhang, MD, Chen Wang, MD, Xu-fei Huang, MD, Tie-nan Zhu, MD, Hua-cong Cai, MD, Xin-xin Cao, MD, Dao-bin Zhou, MD

Blood (2016) 128 (22): 2259.

https://doi.org/10.1182/blood.V128.22.2259.2259

Published: 2016

Journal Articles

Evaluation of Clinicopathologic Characteristics and the BRAF V600E Mutation in Erdheim-Chester Disease Among Chinese Adults

Xin-xin Cao, MD, Jian Sun, MD, Jian Li, MD, Ding-rong Zhong, MD, Na Niu, Bachelor, Ming-hui Duan, MD, Zhi-yong Liang, MD, Dao-bin Zhou, MD

Blood (2015) 126 (23): 3870.

https://doi.org/10.1182/blood.V126.23.3870.3870

Published: 2015

Journal Articles

Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome

Jian Li, Wei Zhang, Li Jiao, Ming-Hui Duan, Hong-Zhi Guan, Wei-Guo Zhu, Zhuang Tian, Dao-Bin Zhou

Blood (2011) 117 (24): 6445–6449.

https://doi.org/10.1182/blood-2010-12-328112

Published: 2011

NARROW

A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD

The Design of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea (HU)

A Prospective, Multicenter Study of Bortezomib, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Idiopathic Multicentric Castleman's Disease

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Treatment Outcome and Prognostic Factors for Adult Langerhans Cell Histiocytosis

Home Treatment of Bortezomib: A Preliminary Exploration of a New Treatment Mode in China

Methotrexate and Cytarabine for Adult Patients with Newly Diagnosed Langerhans Cell Histiocytosis: A Single Arm, Single Center, Prospective Phase 2 Study

Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease

Clinical and PET Responses to Long-Term High-Dose Interferon-α Treatment Among Patients with Erdheim-Chester Disease

Peritransplant Complications and Long-Term Outcomes of Patients with Newly Diagnosed POEMS Syndrome after Upfront Autologous Stem Cell Transplantation

Evaluation of Clinicopathologic Characteristics and the BRAF V600E Mutation in Erdheim-Chester Disease Among Chinese Adults

Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only